ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
15 févr. 2023 08h00 HE
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today provided a...
ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
06 févr. 2023 08h00 HE
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 06, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today provided an...
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
05 janv. 2023 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it...
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
19 déc. 2022 08h30 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. “ProPhase” (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it...
ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022
30 nov. 2022 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be...
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
10 nov. 2022 08h00 HE
|
ProPhase Labs, Inc.
Q3 2022 Net Revenues of $24.2 Million (a Q3 record); Up 155% Year-over-Year Q3 2022 Net Income of $1.0 Million versus a loss in Q3 2021 Q3 2022 adjusted EBITDA of $6.3 million (a Q3...
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
08 nov. 2022 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly...
ProPhase Labs to Present at Investor Summit Group’s Q4 Conference
07 nov. 2022 19h12 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be...
ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time
04 nov. 2022 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on...
ProPhase Labs Announces Collaboration with G42 Healthcare
19 oct. 2022 08h00 HE
|
ProPhase Labs, Inc.
Companies target emerging markets across the globe and joint venture opportunitiesProPhase and G42 Healthcare to explore creation of advanced genomic sequencing facility in the USCompanies enter...